While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...
Radiation bridging therapy during CAR T-cell manufacturing improves outcomes in R/R LBCL compared to systemic bridging therapy. Axi-cel shows superior overall and complete response rates compared to ...
The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL. This is an ASCO Meeting Abstract ...
Researchers aimed to assess prednisolone discontinuation within 3 months of a short-term bridging regimen in patients with newly diagnosed RA managed with a treat‑to‑target approach. A total of 227 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results